2,600 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,600 shares of the biopharmaceutical company’s stock, valued at approximately $612,000.

A number of other hedge funds have also bought and sold shares of the business. Comerica Bank lifted its holdings in Alnylam Pharmaceuticals by 631.7% during the fourth quarter. Comerica Bank now owns 13,991 shares of the biopharmaceutical company’s stock worth $3,292,000 after acquiring an additional 12,079 shares during the period. Voleon Capital Management LP bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $8,749,000. Utah Retirement Systems lifted its holdings in Alnylam Pharmaceuticals by 1.9% during the fourth quarter. Utah Retirement Systems now owns 21,325 shares of the biopharmaceutical company’s stock worth $5,018,000 after acquiring an additional 400 shares during the period. Schonfeld Strategic Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 355.7% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 127,000 shares of the biopharmaceutical company’s stock worth $29,884,000 after acquiring an additional 99,133 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 60.9% during the fourth quarter. AQR Capital Management LLC now owns 813,356 shares of the biopharmaceutical company’s stock worth $191,391,000 after acquiring an additional 307,702 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 1,548 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. This represents a 11.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at $3,654,862.41. The trade was a 4.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock worth $1,875,627 over the last ninety days. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $252.00 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $144.73 and a 52 week high of $304.39. The business has a 50-day simple moving average of $250.53 and a 200 day simple moving average of $253.70. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a market cap of $32.86 billion, a price-to-earnings ratio of -116.13 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same period last year, the firm posted ($0.16) EPS. The firm’s quarterly revenue was up 20.2% compared to the same quarter last year. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ALNY. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Bank of America raised their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a “buy” rating and a $353.00 target price on the stock. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research note on Friday, March 21st. Finally, Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research note on Friday, April 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.